Agios Pharmaceuticals dropped its next-generation sickle cell drug Tuesday after a failed Phase 2 study. Agios stock tumbled.
Why Agios Pharma, A Novo Rival, Just Pulled A Bearish Move
Licensing
Agios Pharmaceuticals (AGIO) dropped its next-generation sickle cell drug Tuesday after a failed Phase 2 study. Agios stock tumbled, threatening a recent breakout. Specifically, the company is discontinuing development of its next-gen PK activator, tebapivat, because it didn't sufficiently differentiate itself from other drugs in its class. Activating PK, or pyruvate kinase, boosts the energy production of red blood cells.…
Agios Reports Neutral Sickle Cell Data, Decides To Stop Development - Agios Pharmaceuticals (NASDAQ:AGIO)
Agios scraps sickle cell drug
Agios’ second shot at sickle cell disease falls short
Arrowhead’s gene silencer competitive with Ionis’ in triglyceride disease
Look out Ionis, here comes Arrowhead with promising hypertriglyceridemia data
Agios Pharmaceuticals stops tebapivat development in sickle cell disease after Phase 2 study fails to prove meaningful…
The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated…
Agios Pharma (AGIO) stock spikes 15% as FDA grants Priority Review for sickle cell disease drug mitapivat. Details here.
Agios' PK activator tebapivat looked no better than the first-generation agents in sickle cell disease, although it's awaiting…
Agios Pharmaceuticals has said it will stop developing its rare blood disorder drug for certain patients with myelodysplastic…
David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease…
